サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：脳脊髄炎の世界市場：産業分析、規模、シェア、成長、動向、予測（2024年～2032年）
市場調査レポート
商品コード
1408994

脳脊髄炎の世界市場：産業分析、規模、シェア、成長、動向、予測（2024年～2032年）

Global Encephalomyelitis Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日: | 発行: Value Market Research | ページ情報: 英文 247 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
脳脊髄炎の世界市場：産業分析、規模、シェア、成長、動向、予測（2024年～2032年）
出版日: 2024年01月01日
発行: Value Market Research
ページ情報: 英文 247 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

脳脊髄炎市場の世界需要は、2022年の212億8,000万米ドルから2030年には348億8,000万米ドル近くの市場規模に達すると推定され、調査期間2023年～2030年のCAGRは6.37%です。

脳脊髄炎は、脳（脳炎）と脊髄（脊髄炎）の両方の炎症を指します。脳脊髄炎は、感染症、自己免疫疾患、その他の炎症プロセスによって引き起こされます。この疾患は、激しい症状を伴って突然発症する急性の場合もあれば、長期にわたる、あるいは再発性の炎症を伴う慢性の場合もあります。

市場力学

脳脊髄炎の理解と管理における進歩・開発の促進要因には、神経学と免疫学における継続的な研究の進歩が含まれます。こうした取り組みは、診断ツールや治療法の改善に寄与しています。ADEMやME/CFSなど様々な脳脊髄炎に焦点を当てた啓発活動の増加は、早期診断と早期介入を促進する上で重要な役割を果たしています。医療画像や診断ツールの技術革新は、脳脊髄炎を正確に診断・監視する能力をさらに高め、研究や臨床の方向性を形成しています。ヘルスケア専門家、研究者、患者支援団体、製薬企業間の協力的な取り組みにより、知識やリソースの交換が促進され、この分野の進歩が促進されます。脳脊髄炎に対する新たな治療法や治療アプローチの発見・開発は、医療および製薬分野への関心と投資の増加に寄与し、この複雑な病状を管理するための進歩を促進します。

この調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を対象としています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、脳脊髄炎の世界市場における各セグメントを包括的に評価することもできます。脳脊髄炎産業の成長と動向は、この研究に全体的なアプローチを提供します。

地域分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける脳脊髄炎市場の現在および将来の需要を強調する地域展望をカバーします。さらに、本レポートでは、すべての主要地域における個々のアプリケーションセグメントの需要、推定と予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 脳脊髄炎：産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 脳脊髄炎の世界市場分析：エンドユーザー別

  • 概要：エンドユーザー別
  • 実績データと予測データ
  • 分析：エンドユーザー別
  • 診療所
  • 病院
  • その他

第6章 脳脊髄炎の世界市場分析：治療法別

  • 概要：治療法別
  • 実績データと予測データ
  • 分析：治療法別
  • 手術
  • プラズマフェレーシス
  • 薬物治療
  • その他

第7章 脳脊髄炎の世界市場分析：タイプ別

  • 概要：タイプ別
  • 実績データと予測データ
  • 分析：タイプ別
  • 馬脳脊髄炎
  • 関連脳脊髄炎
  • 抗MOG
  • 散在性脳脊髄炎
  • 急性播種性脳脊髄炎
  • AIDS関連脳脊髄炎
  • その他

第8章 脳脊髄炎の世界市場分析：地域別

  • 地域別の展望
  • イントロダクション
  • 北米の売上分析
    • 概要・実績・予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の売上分析
    • 概要・実績・予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域の売上分析
    • 概要・実績・予測
    • アジア太平洋地域：セグメント別
    • アジア太平洋地域：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋地域
  • ラテンアメリカの売上分析
    • 概要・実績・予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東とアフリカの売上分析
    • 概要・実績・予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第9章 脳脊髄炎企業の競合情勢

  • 市場競合
  • 提携・協力・合意
  • 合併・買収
  • 新製品の上市
  • その他の開発

第10章 企業プロファイル

  • 企業シェア分析
  • 市場集中度
  • Oncomed Pharmaceuticals
  • Pfizer Inc.
  • Immunomedics
  • Takeda Pharmaceuticals
  • AbbVie Inc.
  • Janssen Biotech Inc.
  • AstraZeneca Plc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Bayer AG
  • Merck & Co. Inc.
  • Amgen Inc.
  • Spectrum Pharmaceuticals Inc.
  • GlaxoSmithKline Plc.
  • Sanofi
  • Bristol-Myers Squibb Company
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by End-Users (USD MN)
  • Clinics Market Sales by Geography (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis Market by Treatment (USD MN)
  • Surgery Market Sales by Geography (USD MN)
  • Plasmapheresis Market Sales by Geography (USD MN)
  • Drug Treatment Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis by Type (USD MN)
  • Equine Encephalomyelitis Market Sales by Geography (USD MN)
  • Associated Encephalomyelitis Market Sales by Geography (USD MN)
  • AntiMOG Market Sales by Geography (USD MN)
  • Encephalomyelitis Disseminata Market Sales by Geography (USD MN)
  • Acute Disseminated Encephalomyelitis Market Sales by Geography (USD MN)
  • AIDS-Related Encephalomyelitis Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Encephalomyelitis Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Encephalomyelitis Report
  • Market Research Process
  • Market Research Methodology
  • Global Encephalomyelitis Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by End-Users
  • Market Attractiveness Analysis by Treatment
  • Market Attractiveness Analysis by Type
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by End-Users (USD MN)
  • Clinics Market Sales by Geography (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Treatment (USD MN)
  • Surgery Market Sales by Geography (USD MN)
  • Plasmapheresis Market Sales by Geography (USD MN)
  • Drug Treatment Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Type (USD MN)
  • Equine Encephalomyelitis Market Sales by Geography (USD MN)
  • Associated Encephalomyelitis Market Sales by Geography (USD MN)
  • AntiMOG Market Sales by Geography (USD MN)
  • Encephalomyelitis Disseminata Market Sales by Geography (USD MN)
  • Acute Disseminated Encephalomyelitis Market Sales by Geography (USD MN)
  • AIDS-Related Encephalomyelitis Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112113252

The global demand for Encephalomyelitis Market is presumed to reach the market size of nearly USD 34.88 BN by 2030 from USD 21.28 BN in 2022 with a CAGR of 6.37% under the study period 2023 - 2030.

Encephalomyelitis refers to the inflammation of both the brain (encephalo) and the spinal cord (myelitis). This may be caused due to infections, autoimmune disorders, and other inflammatory processes. This condition can be acute, meaning it occurs suddenly with severe symptoms, or it can be chronic, involving long-term or recurrent inflammation.

MARKET DYNAMICS

The factors driving progress and developments in the understanding and management of encephalomyelitis include ongoing research advances in neurology and immunology. These efforts contribute to improved diagnostic tools and treatment options. Increased awareness initiatives focused on various forms of encephalomyelitis, such as ADEM or ME/CFS, play a vital role in promoting early diagnosis and intervention. Technological innovations in medical imaging and diagnostic tools further enhance the ability to accurately diagnose and monitor encephalomyelitis, shaping the direction of research and clinical practices. Collaborative efforts among healthcare professionals, researchers, patient advocacy groups, and pharmaceutical companies facilitate the exchange of knowledge and resources, fostering progress in the field. The discovery and development of new treatments or therapeutic approaches for encephalomyelitis contribute to increased interest and investment in the medical and pharmaceutical sectors, promoting advancements in managing this complex medical condition.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of encephalomyelitis. The growth and trends of encephalomyelitis industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the encephalomyelitis market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By End-Users

  • Clinics
  • Hospitals
  • Others

By Treatment

  • Surgery
  • Plasmapheresis
  • Drug Treatment
  • Others

By Type

  • Equine Encephalomyelitis
  • Associated Encephalomyelitis
  • AntiMOG
  • Encephalomyelitis Disseminata
  • Acute Disseminated Encephalomyelitis
  • AIDS-Related Encephalomyelitis
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Encephalomyelitis market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Encephalomyelitis market include Oncomed Pharmaceuticals, Pfizer Inc., Immunomedics, Takeda Pharmaceuticals, AbbVie Inc., Janssen Biotech, Inc., AstraZeneca Plc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Merck & Co. Inc., Amgen Inc., Spectrum Pharmaceuticals Inc., GlaxoSmithKline Plc., Sanofi, and Bristol-Myers Squibb Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . ENCEPHALOMYELITIS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By End-Users
    • 3.7.2 Market Attractiveness Analysis By Treatment
    • 3.7.3 Market Attractiveness Analysis By Type
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ENCEPHALOMYELITIS MARKET ANALYSIS BY END-USERS

  • 5.1 Overview by End-Users
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by End-Users
  • 5.4 Clinics Historic and Forecast Sales by Regions
  • 5.5 Hospitals Historic and Forecast Sales by Regions
  • 5.6 Others Historic and Forecast Sales by Regions

6 . GLOBAL ENCEPHALOMYELITIS MARKET ANALYSIS BY TREATMENT

  • 6.1 Overview by Treatment
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Treatment
  • 6.4 Surgery Historic and Forecast Sales by Regions
  • 6.5 Plasmapheresis Historic and Forecast Sales by Regions
  • 6.6 Drug Treatment Historic and Forecast Sales by Regions
  • 6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL ENCEPHALOMYELITIS MARKET ANALYSIS BY TYPE

  • 7.1 Overview by Type
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Type
  • 7.4 Equine Encephalomyelitis Historic and Forecast Sales by Regions
  • 7.5 Associated Encephalomyelitis Historic and Forecast Sales by Regions
  • 7.6 AntiMOG Historic and Forecast Sales by Regions
  • 7.7 Encephalomyelitis Disseminata Historic and Forecast Sales by Regions
  • 7.8 Acute Disseminated Encephalomyelitis Historic and Forecast Sales by Regions
  • 7.9 AIDS-Related Encephalomyelitis Historic and Forecast Sales by Regions
  • 7.10. Others Historic and Forecast Sales by Regions

8 . GLOBAL ENCEPHALOMYELITIS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. South East Asia Sales Analysis
    • 8.5.10. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE ENCEPHALOMYELITIS COMPANIES

  • 9.1. Encephalomyelitis Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF ENCEPHALOMYELITIS INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Oncomed Pharmaceuticals
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. Pfizer Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Immunomedics
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Takeda Pharmaceuticals
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. AbbVie Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Janssen Biotech Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. AstraZeneca Plc.
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. Eli Lilly and Company
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. F. Hoffmann-La Roche Ltd.
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. Novartis AG
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments
  • 10.13. Bayer AG
    • 10.13.1. Company Overview
    • 10.13.2. Company Revenue
    • 10.13.3. Products
    • 10.13.4. Recent Developments
  • 10.14. Merck & Co. Inc.
    • 10.14.1. Company Overview
    • 10.14.2. Company Revenue
    • 10.14.3. Products
    • 10.14.4. Recent Developments
  • 10.15. Amgen Inc.
    • 10.15.1. Company Overview
    • 10.15.2. Company Revenue
    • 10.15.3. Products
    • 10.15.4. Recent Developments
  • 10.16. Spectrum Pharmaceuticals Inc.
    • 10.16.1. Company Overview
    • 10.16.2. Company Revenue
    • 10.16.3. Products
    • 10.16.4. Recent Developments
  • 10.17. GlaxoSmithKline Plc.
    • 10.17.1. Company Overview
    • 10.17.2. Company Revenue
    • 10.17.3. Products
    • 10.17.4. Recent Developments
  • 10.18. Sanofi
    • 10.18.1. Company Overview
    • 10.18.2. Company Revenue
    • 10.18.3. Products
    • 10.18.4. Recent Developments
  • 10.19. Bristol-Myers Squibb Company
    • 10.19.1. Company Overview
    • 10.19.2. Company Revenue
    • 10.19.3. Products
    • 10.19.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies